Log in to your Inderes Free account to see all free content on this page.
Pila Pharma
5.8 SEK +12.84%HC Andersen Capital has previously received payment from Pila Pharma for a Digital IR/Corporate Visibility agreement. This means that there may be paid material that is not updated. See disclaimer.
1 investor is following this company
Pila Pharma operates in the pharmaceutical industry. The company conducts clinical trials in phase 2 with pharmaceuticals for type 2 diabetes. The main product is a tablet that is taken orally at an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. The business with associated research is conducted in Sweden.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
PILA
Daily low / high price
5.34 / 6.14
SEK
Market cap
157.33M SEK
Turnover
1.6M SEK
Volume
285K
Latest videos
Financial calendar
Interim report
27.08.2024
Annual report
27.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Dorte X. Gram genom bolag | 21.8 % | 21.8 % |
Vimpu Intressenter AB | 16.7 % | 16.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
PILA PHARMA INKS AGREEMENT WITH LINDUS HEALTH ABOUT NEXT CLINICAL TRIAL WITH SAFETY AND OBESITY READOUTS
PILA PHARMA'S BOARD OF DIRECTORS HAS RESOLVED TO CARRY OUT A DIRECTED ISSUE OF SHARES OF APPROXIMATELY SEK 10.0 MILLION
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio